Core Insights - Bayer AG has received preliminary approval for a proposed class action settlement regarding Roundup litigation, which aims to resolve claims that Roundup caused non-Hodgkin lymphoma [1][10] - The settlement framework is part of Bayer's strategy to manage its long-standing Roundup litigation exposure, which has negatively impacted investor sentiment [3] - A fairness hearing is scheduled for July 9, 2026, to determine final approval of the settlement [2] Legal Developments - The Missouri Circuit Court judge's approval allows for a 90-day opt-out and objection period for potential class members, ending on June 4, 2026 [2] - The U.S. Supreme Court is reviewing the Durnell case, which may influence state-level failure-to-warn claims related to Roundup [4] - Bayer has set aside $11.3 billion (€9.6 billion) for glyphosate litigation as of December 31, 2025, reflecting the significant costs incurred from ongoing lawsuits [7][10] Company Performance - Bayer's shares have increased by 64.1% over the past year, significantly outperforming the industry average gain of 8.6% [9] - Despite missing sales targets in the fourth quarter, Bayer's overall performance in 2025 was strong, driven by new products in the Pharmaceutical division [11] - The FDA has granted approvals for several new drugs, including elinzanetant and Hyrnuo, which are expected to enhance sales [12][13] Future Outlook - Bayer anticipates that litigation impacts will continue to affect its cash position in 2026 [14] - The company is focused on expanding its product portfolio and addressing legal liabilities to improve investor confidence and financial stability [3][11]

Core Viewpoint - A group of 14 law firms representing nearly 20,000 plaintiffs is challenging Bayer's proposed class-action settlement regarding Roundup litigation, expressing concerns about fairness for cancer sufferers [1][2][3] Group 1: Settlement Proposal Details - Bayer announced a proposed class-action settlement of $7.25 billion on February 17, offering payments between $10,000 and $165,000 to users of glyphosate-based products who have or may develop non-Hodgkin lymphoma (NHL) [6][7] - The settlement proposal includes a provision for preliminary court approval within a 15-day period, which the opposing law firms are seeking to extend by 60 days for broader public participation and scrutiny [5] Group 2: Concerns Raised by Opposing Law Firms - The law firms argue that the settlement appears "unprecedented" and raises multiple "red flags," suggesting it heavily favors occupational users of Roundup, such as farmers, over residential users [3][8] - The proposed payment schedule indicates that an occupational claimant diagnosed before age 60 with aggressive NHL could receive an average of $165,000, while a residential user with similar traits would average only $40,000 [8] Group 3: Bayer's Legal Challenges - Since acquiring Monsanto in 2018, Bayer has faced over 100,000 lawsuits related to Roundup, resulting in billions of dollars paid in settlements and jury verdicts to individuals claiming NHL due to glyphosate exposure [7]

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The request is the first major organized pushback against Bayer's attempt to resolve most of the 65,000 remaining Roundup claims in state and federal courts. Reporting by Diana Novak Jones in Chicago, Editing by Alexia Garamfalvi Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Read Next Governmentcategory Google legally reported user's child sex ab ...

Core Viewpoint - Bayer AG proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer, originally made by Monsanto, which Bayer acquired in 2018 for over $60 billion [1] Group 1: Settlement Details - The proposed settlement aims to provide closure for Bayer, reducing litigation uncertainty and potential exposure from future Supreme Court rulings [2] - Monsanto will fund the settlement through capped annual payments over up to 21 years, totaling as much as $7.25 billion, and has agreed to settle additional Roundup cases under confidential terms [3] - The settlement proposal was filed in Missouri's St. Louis Circuit Court, where many lawsuits were initiated, claiming inadequate warnings about non-Hodgkin lymphoma risks associated with glyphosate [4] Group 2: Legal Context - The proposed settlement comes as the U.S. Supreme Court prepares to hear arguments regarding Bayer's assertion that EPA's approval of Roundup without a cancer warning should nullify state court claims, and the settlement will not impact this case [5] - Bayer's Monsanto unit secured a significant legal victory when a Washington state appeals court overturned a $185 million verdict against the company related to chemical contamination [6] - The Trump administration backed Bayer in its Roundup cases, urging the Supreme Court to limit state-law claims, which could provide regulatory clarity for farmers [7]

Group 1: Executive Order and Domestic Supply - President Trump signed an executive order on Feb. 18 to mobilize the Defense Production Act (DPA) to secure the domestic supply of elemental phosphorus and glyphosate-based herbicides [1] - Elemental phosphorus has been designated as a "scarce material that is critical to national defense and security," highlighting its importance in military readiness and agricultural productivity [2] - The U.S. currently relies on Bayer AG as the sole domestic producer of elemental phosphorus, raising concerns about vulnerability to foreign supply chains [2] Group 2: Impact on Bayer and Agribusiness - The executive order places Bayer's U.S. operations, particularly its Monsanto division, under federal protection to ensure corporate viability [4] - Bayer is facing litigation related to its glyphosate-based Roundup, with a proposed settlement of $7.25 billion for lawsuits claiming the product causes cancer [5] - Following the executive order, agribusiness ETFs such as the VanEck Agribusiness ETF and iShares MSCI Global Agriculture Producers ETF may attract increased investor interest due to the sector's new government-protected status [6] Group 3: National Defense and Resource Allocation - The order emphasizes the importance of domestic elemental phosphorus mining for American economic and national security, as it is a key input for various defense technologies [7] - The presidential authority is delegated to the Secretary of Agriculture, in consultation with the Secretary of War, to prioritize contracts and allocate materials necessary for maintaining an adequate supply of these critical inputs [8]

The Missouri judge overseeing Bayer AG’s effort to resolve current and future Roundup lawsuits through a class-action case is known as a no-nonsense jurist who will closely scrutinize the proposed $7.25 billion settlement https://t.co/cUrDyQcou8 ...

Core Insights - A new settlement of $7.25 billion has been reached between Bayer and a group of cancer patients, potentially concluding a significant number of lawsuits against the company regarding allegations of failing to warn consumers about cancer risks [1] Group 1 - The settlement amount of $7.25 billion indicates the scale of the legal challenges faced by Bayer [1] - The lawsuits primarily focus on allegations that Bayer did not adequately inform consumers about the cancer risks associated with its products [1]

Group 1 - Bayer's Monsanto unit proposed a $7.25 billion nationwide class settlement to resolve current and future lawsuits alleging that Roundup caused cancer, aiming to end years of litigation [1] - The settlement would provide payments over up to 21 years, funding a claims program for individuals alleging Roundup exposure caused non-Hodgkin lymphoma, with individual payments varying based on age, exposure, and severity of cancer [1] - The settlement is designed to cover the majority of the existing 65,000 claims Bayer faces and also compensate future claimants diagnosed with non-Hodgkin lymphoma [1] Group 2 - Bayer can terminate the settlement if insufficient plaintiffs support it, but the number of required opt-ins has not been disclosed, leaving uncertainty about court approval [1] - Some law firms representing Roundup plaintiffs support the settlement, but others are still reviewing it, with at least one firm signaling opposition [1] - The lengthy claims program aims to address future cancer claims, with the company required to provide annual notices to alert potential future claimants [1] Group 3 - Bayer has a case before the U.S. Supreme Court that could impact the litigation landscape, as the court will decide if Bayer can be sued under state law for failing to warn about cancer risks associated with Roundup [1] - A favorable ruling for Bayer could eliminate thousands of claims, but plaintiffs may still pursue other liability theories, making the settlement necessary [1] - The proposed deal does not guarantee closure, as it could fall apart without sufficient support or court approval, and claimants can opt out to pursue their claims independently [1]

Core Points - President Trump issued an executive order to promote domestic production of phosphorus and glyphosate, citing their importance for national defense and food security [2][5] - The order mandates Agriculture Secretary Brooke Rollins to implement regulations to increase the supply of these chemicals [4] - There is currently only one domestic producer of elemental phosphorus and glyphosate-based herbicides, making the supply chain vulnerable to foreign threats [5] Company Insights - Bayer, the manufacturer of glyphosate-based herbicide Roundup, is involved in ongoing litigation regarding the chemical's alleged links to cancer, with a proposed settlement of $7.25 billion for lawsuits [3] - Monsanto, now owned by Bayer, emphasized the necessity for U.S. farmers to access domestically produced crop protection tools like glyphosate and stated compliance with the executive order [7] - The executive order reflects a shift in the stance of health officials, who previously expressed concerns about glyphosate but now recognize its importance for farmers [6]

Bayer CEO Bill Anderson’s effort to extricate the company from the years-long legal battles related to its Roundup pesticide is facing some skepticism from investors https://t.co/Bct8kjW2z7 ...